GlycoMimetics Inc. Completes 1-for-100 Reverse Stock Split Amid Merger with Crescent Biopharma
GlycoMimetics Inc. has completed a 1-for-100 reverse stock split as part of its merger with Crescent Biopharma. Each share of Crescent common stock was converted into 0.1445 shares of the new entity. The combined company now has approximately 19.5 million shares outstanding and will trade on Nasdaq under the ticker symbol "CBIO." The new CUSIP number is 38000Q201.
GlycoMimetics Inc. has completed a reverse stock split at a ratio of 1-for-100 shares as part of its merger with Crescent Biopharma. Following the merger, each outstanding share of Crescent common stock was converted into 0.1445 shares of the new combined company. The new CUSIP number for the company is 38000Q201, and approximately 19.5 million shares of the combined company’s common stock and equivalents are now outstanding. The company’s shares are set to begin trading on the Nasdaq under the ticker symbol “CBIO.” Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlycoMimetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-060714), on June 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
